Inhibitory effect of TRK-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis

Pharmacology. 1998 May;56(5):237-41. doi: 10.1159/000028203.


TRK-530 is a novel synthetic bisphosphonate compound which exhibits inhibitory activity in the rat adjuvant arthritis (AA) model. We found that, during AA development, the concentrations of cytokine-induced neutrophil chemoattractant-1 (CINC-1) and tumor necrosis factor alpha (TNF-alpha) in the bone marrow increased, and that administration of TRK-530 decreased the concentrations of these cytokines. The suppression of these concentration increases paralleled the inhibition of paw edema. Paw edema inhibition by TRK-530 in rat AA may be the result of decreasing CINC-1 and TNF-alpha concentrations.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Arthritis, Experimental / metabolism*
  • Bone Marrow / drug effects
  • Bone Marrow / metabolism*
  • Chemokine CXCL1
  • Chemokines, CXC / metabolism
  • Chemotactic Factors / metabolism
  • Cytokines / metabolism*
  • Diphosphonates / pharmacology*
  • Female
  • Foot / pathology
  • Growth Substances / metabolism
  • Inflammation / metabolism*
  • Intercellular Signaling Peptides and Proteins*
  • Rats
  • Rats, Inbred Lew
  • Tumor Necrosis Factor-alpha / metabolism


  • Anti-Inflammatory Agents, Non-Steroidal
  • Chemokine CXCL1
  • Chemokines, CXC
  • Chemotactic Factors
  • Cxcl1 protein, rat
  • Cytokines
  • Diphosphonates
  • Growth Substances
  • Intercellular Signaling Peptides and Proteins
  • TRK 530
  • Tumor Necrosis Factor-alpha